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Introduction
The field of tissue engineering holds great promise for the 
repair or regeneration of damaged and diseased tissue. 
Researchers in bone tissue engineering are working to 
develop alternatives to allogeneic and autologous bone 
grafts in order to address the growing clinical needs and to 
avoid the morbidities associated with harvesting bone graft. 
The introduction of mesenchymal stromal cells (MSCs) has 
been tested in the repair of large bony defects in animal 
models and in humans, with variable degrees of success.1–3 
The inclusion of undifferentiated mesenchymal cells and/or 
growth factors to biological scaffolds should enhance the 
bone regeneration abilities of the material.1,4 One of the 
main challenges of the reconstruction of the created defects 
of the jaw bones following the resection for oral cancer is 
the deficient blood supply. This deficiency is due to either 
the pathological condition that affects the blood vessels in 
the head and neck region or fibrosis of the vascular bed 
resulting from post-operative radiotherapy. Therefore, it is a 
major challenge to apply the recent advances in tissue bio-
engineering for bone regeneration in the oro-facial regions.
Recently, the potential for skeletal muscle to form bone 
has been explored.5 This is seen most dramatically in the 
genetic disease fibrodysplasia ossificans progressiva 
(FOP), where patients develop a second skeleton as muscle 
spontaneously ossifies.6 Heterotopic ossification of muscle 
is also common after joint replacement surgery and follow-
ing blast injuries.7,8 Although these are troubling medical 
conditions, they suggest novel opportunities for regenera-
tive medicine to address circumstances where it is neces-
sary to grow large amounts of new bone which requires a 
rich blood supply as seen in muscular tissue. Therefore, 
there is enormous interest in developing a biomimetic scaf-
fold that could be injected in muscular tissue to stimulate 
osteogenesis for potential reconstruction of critical-size 
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Cements for maxillofacial reconstruction of jaw defects through calcification of rotated muscle have been tested. 
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bony defects in the oro-facial region, which will be the next 
step of this study.
Various bio-scaffolds have been designed to replace 
resected tissue in the oro-facial region. The potential option 
of using an injectable scaffold is an attractive choice for 
clinicians. Injectable materials would reduce surgical inva-
siveness, minimizing the risk of infection, scar formation 
and the cost of treatment.9 The ideal injectable scaffold 
should be injected in a liquid form and undergo a gelation 
or setting process once in situ. In open surgery, the use of 
such a material allows surgeons to fill to reconstruct bone 
defects.10
Calcium sulphate (CS), or plaster of Paris, has been used 
as a bone substitute for over 100 years and has been proved 
to be safe and biocompatible.11 However, it has been shown 
that the resorption of CS is faster than the formation of new 
bone, which precludes its use in the reconstruction of large 
bony defects.12 To overcome this limitation, composite 
injectable cements have been developed by adding more 
slowly resorbing materials to CS cements.12,13 A composite 
injectable material based on 60% calcium sulphate hemihy-
drate (CSH) and 40% hydroxyapatite (HA) has been devel-
oped (Cerament™).13 When this material is mixed with a 
liquid phase, it forms a resorbable phase consisting of cal-
cium sulphate dihydrate (CSD) and unreacted HA. The 
CSD phase is absorbed in the body creating pores, thereby 
permitting new bone ingrowth. The HA phase lasts longer 
(9–12 months), hence promoting osteoconduction and 
potentially osseoinduction of bone into the defect. The 
compressive strength of the material after setting was esti-
mated to be 20 MPa and reached 13 MPa after 10 days of 
immersion at simulated body fluid (SBF).13,14
Cerament cement is available commercially for spinal 
fusion (Cerament Spine Support) and as filler for bone 
cavities (Cerament Bone Void Filler) with different for-
mulations, setting speeds and mechanical properties.13–20 
To our knowledge, there are no published data testing 
these two materials at the cellular level. The biocompati-
bility testing was carried out by implanting the material at 
ectopic and orthotropic sites using rat model.14 The appli-
cation of the material as a biomimetic injectable scaffold 
(loaded with cytokines and seeded with undifferentiated 
mesenchymal cells) for maxillofacial reconstruction has 
not been considered, and the suitability of the material for 
this application has not yet been tested. This in vitro study 
is part of a comprehensive research programme to take the 
material from the laboratory to clinical maxillofacial 
application. This is an essential step before applying the 
material in a preclinical model. This model has been 
established by our team for construction of critical-size 
osteoperiosteal continuity defect of the mandible.21 Thus, 
this is the first study conducted to characterize the interac-
tion between Cerament and the undifferentiated rabbit 
mesenchymal stromal cells (rMSCs) and to inform the 
optimum surgical approach.
Therefore, the aims of this study are to characterize the 
interaction between two types of Cerament and the undif-
ferentiated rMSCs and to assess the overall suitability of 
the materials as biomimetic scaffolding for potential clini-
cal applications.
Materials and methods
Cement mixing and sample preparation
The materials tested in this experiment have the same pow-
der consisting of 60% α-CSH and 40% HA, provided by 
Bone Support AB (Lund, Sweden). The difference lies in the 
powder-to-liquid ratio and the viscosity of the liquid phase, 
which is an iodine solution. In Cerament Bone Void Filler, 
the liquid phase is Cerament ⎪C-Tru with iodine concentra-
tion of 180 mg/mL; the powder was mixed at a ratio of 1 
g/0.43 mL of liquid. Cerament Spine Support powder was 
mixed with Cerament ⎪C-Tru with iodine concentration of 
300 mg/mL as an alternative radiopacifier and mixed in a 
powder-to-liquid ratio of 1 g/0.5 mL. The material is meta-
stable below 40°C at atmospheric pressure and hydrates on 
contact with water to form CSD as in equation (1). The crys-
tals of CSD which form are about 4–6 µm long and flat in 
shape, and crystal growth occurs in all directions forming a 
matrix of well-interconnected crystals. The setting reaction 
of the cement is slightly exothermic, at 37°C; the setting time 
was 7 min and the pH of the injected cement was 7.5.14,16
 CaSO4.1/2 H2O + 3/2 H2O  CaSO4.2H2O (1)
Once the cement reached a paste-like consistency, 0.5 
mL of cement was evenly spread over a glass slide. Before 
the material was set, it was divided into 5 × 5 × 1 mm3 
squares, which were used for cell culture, cytotoxicity and 
proliferation tests. The samples were prepared in triplicate; 
nine samples were prepared and examined at each time 
point for both cements.
Biocompatibility assays using MG-63
Methyl thiazolyl tetrazolium. MG-63 cells were cultured in 
filtered Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% foetal calf serum (FCS; Life Tech-
nologies, Paisley, UK) and a 2% a mixture of streptomycin, 
penicillin, fluconazole and glutamine (Life Technologies) 
and maintained at 95% humidity at 37°C and 5% CO2. 
When the cells reached confluence, they were passaged 
from the tissue culture flasks; this involved removal of the 
culture media and washing them in Dulbecco’s phosphate 
buffered saline (DPBS) twice before removing the cells 
with a trypsin/ethylenediaminetetraacetic acid (EDTA) 
solution (Sigma–Aldrich, UK) for 5 min at 37°C. The 
trypsin was inactivated by the addition of an equal volume 
of DMEM supplemented with 10% FCS, and the cells were 
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collected by centrifugation. At this point, the cells were 
resuspended in 1 mL of DMEM supplemented with 10% 
FCS. The prepared cement squares of both Cerament Bone 
Void Filler and Cerament Spine Support were placed in 
24-well plates. The prepared cell suspension was seeded on 
the surface of the prepared squares at a cell density of 1 × 
103 cells/cm2, 15 min after mixing the cement. Wells con-
taining cells only (no cement) were used as controls. The 
plates were incubated and maintained at 95% humidity at 
37°C and 5% CO2. Cell viability was determined after 1, 3 
or 7 days culture using the standard colorimetric methyl 
thiazolyl tetrazolium (MTT) assay to detect the presence of 
living cells.22,23 Within active, living cells, the yellow MTT 
substrate is reduced by mitochondrial enzymes to form an 
insoluble purple formazan crystal product. The reduction of 
this yellow MTT substrate only takes place when mitochon-
drial enzymes are active, and therefore, conversion is often 
used as a measure of viable (living) cells; 100 µL of MTT 
(Sigma–Aldrich, UK) was added into all wells (the experi-
mental and control) in a plate. The plate was incubated for 
1.5 h. Then, the supernatant of each well was removed, and 
200 µL dimethyl sulphoxide (DMSO) was added into all 
wells. An optical density (OD) reading was obtained to cor-
relate directly with cell number and was used to determine 
the relative number of live cells on each cement, that is, the 
absorbance is directly proportional to the cell numbers. The 
plate reader (Dynatech MR7000, Channel Islands, UK) was 
adjusted to a wavelength of 550 nm.
Live/dead assay. MG-63 cells were plated onto the prepared 
cement discs for both cements at a density of 1 × 104 cells/
mL in 2 mL of culture medium. The plate was incubated at 
37°C and 5% CO2 for three time points: 1, 3 and 7 days. 
Live/dead stain was prepared by adding 2 µmol/L acetome-
thoxy derivate of calcein (calcein-AM) and 2 µmol/L ethid-
ium homodimer-1 per millilitre of media. The construct was 
then left in the incubator for 30 min; afterwards, the dye was 
removed and replaced with 1 mL of DMEM. The examina-
tion was carried out on the same day using fluorescent 
microscopy (Leica-Letiz DM IRB, Wetzlar, Germany), three 
random fields of view were chosen at low objective 5× mag-
nification and then five areas were magnified and imaged at 
10× objective using an Axiovision camera (Zeiss, Jena, Ger-
many; total of 3 construct yielded 15 images for each 
cement).24,25 Mean live and mean dead cell numbers were 
estimated from the five images. Then, the percentage of via-
ble cell was counted by dividing the mean number of live 
cells by the sum of the total cell count (live and dead cells).
rMSCs harvesting, isolation, characterization 
and osteogenic potential testing
rMSCs harvesting, culturing and characterization. Bone mar-
row was aspirated from the anterior iliac spine of sedated 
rabbits using 20-mL heparinized syringes. The mononuclear 
cells were separated by centrifuging at 900g for 10 min at 
room temperature to remove the fat and debris and then 
lysed. The remaining cells were loaded into 12-mL tubes 
containing Ficoll-paque, a density medium (GE Healthcare 
Life Sciences, Buckinghamshire, UK) and centrifuged at 
800g for 30 min. A cell count was performed using a Neu-
bauer haemocytometer, and then, the cells were resuspended 
in 10 mL of Alpha Minimum Essential Medium (α-MEM; 
Sigma–Aldrich, UK).26 The rMSCs, at a density of 2 × 106 
cells/mL, were cultured into filtered α-MEM supplemented 
with 10% FCS; Life Technologies) and 2% of a mixture of 
streptomycin, penicillin, fluconazole and glutamine (Life 
Technologies) and maintained at 95% humidity at 37°C and 
5% CO2. The cells took 3–5 weeks to reach the number of 
cells required for potential implantation.
Once rMSCs with a typical fibroblast-like morphology 
had reached confluence, they were passaged from the tissue 
culture flasks by removing the culture media and washed in 
DPBS (Sigma–Aldrich, UK) twice before removing the 
cells with a 2% trypsin-EDTA solution (Sigma–Aldrich, 
USA) for 5 min at 37°C. Cells characterization was carried 
out for specific rMSCs protein surface markers CD44 
(Abbiotec, CA, USA), CD166 (Abcam, UK) and negative 
for CD34 (Abbiotec, San Diago, USA) using immunofluo-
rescent stains as described below.27 Cells were left for 3 
days in conventional culture medium, namely, DMEM cul-
ture medium, supplemented with 10% FCS, before being 
checked for osteogenic potential using osteogenic medium, 
where they were cultured for 28 days before the assessment 
was performed. The osteogenic medium was prepared by 
using 500 mL of α-MEM supplemented with 10% foetal 
bovine serum (FBS), 100 nmol/L dexamethasone (Sigma–
Aldrich, UK) and 50 µmol/L ascorbic acid-2-phosphates 
(Sigma–Aldrich, UK). Then, the differentiation potential of 
rMSCs was assessed using an immunofluorescent stain for 
osteocalcin (OCN; AbD Serotec, USA). Furthermore, gene 
expressions for OCN (Invitrogen, UK) and osteopontin 
(OPN; Invitrogen, UK) were also carried out.28
Messenger RNA (mRNA) expression profiles to test the osteo-
genic potential of rMSCs. Total RNA was isolated from 
rMSCs after 21 days of cell culture in osteogenic medium 
as described above. RNA was isolated using a Qiagen 
RNeasy Mini Kit (Life Technologies). Synthesis and 
amplification of DNA were performed with the Qiagen 
one-step reverse transcriptase–polymerase chain reaction 
(RT-PCR) kit. Six pairs of primers were tested; their 
sequences are listed in Table 1. Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was used as the endoge-
nous control. DNA amplification was carried out through 
different thermal consecutive cycles (Thermal cycle, 
Master Cycle personal, Eppendorf, Germany) with an 
annealing temperature of 45°C and incubation for 30 s. 
PCR reactions were resolved on 1.2% agarose gel in tris-
borate-EDTA (TBE) buffer.29
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rMSCs response upon direct cell seeding
A direct seeding approach was used to assess early rMSC 
response before in-gel seeding to test cell adhesion and prolif-
eration on the surface of the cement. Cement constructs were 
prepared using Cerament Spine Support due to superior bio-
compatibility, which was mixed with 0.4 mg/mL of bone mor-
phogenetic protein-7 (BMP-7).30 BMP-7 has been selected 
because it has reported successful clinical applications in the 
maxillofacial regions.22,31 Nine constructs of each cement 
were prepared for rMSC seeding. After 1 or 3 days of cell cul-
ture, rMSCs on the test material were prepared according to an 
established protocol for immunofluorescent cytoskeletal stain-
ing.27 After 3 days of culture, rMSCs were fixed in 4% formal-
dehyde/phosphate buffered saline (PBS) with 1% sucrose, at 
37°C for 15 min to allow the viewing of individual cells. Once 
fixed, the samples were washed with PBS, and a permeabilis-
ing buffer (10.3 g sucrose, 0.292 g NaCl, 0.06 g MgCl2·6H2O, 
0.476 g 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
(HEPES) buffer and 0.5 mL Triton X, in 100 mL water, pH 
7.2) was added and kept at 4°C for 5 min. The samples were 
then incubated at 37°C for 5 min in 1% bovine serum albumin 
(BSA)/PBS. This was followed by the addition of anti-vinculin 
primary antibody (Antibodies-online.com; 1:100 in 1% BSA/
PBS, mouse monoclonal anti-human cross-reacted with rabbit 
IgG for 1 h at 37°C). Simultaneously, rhodamine-conjugated 
phalloidin (Invitrogen, Carlsbad, CA, USA) was added for the 
duration of this incubation (1:100 in 1% BSA/PBS; Molecular 
Probes, OR, USA). The samples were next washed in 0.5% 
Tween 20/PBS (3 × 5 min). A secondary, biotin-conjugated 
antibody (1:50 in 1% BSA/PBS, monoclonal anti-mouse IgG; 
Vector Laboratories, UK) was added for 1 h (37°C) followed 
by washing. A fluorescein isothiocyanate (FITC)-conjugated 
streptavidin third layer was added (1:50 in 1% BSA/PBS; 
Vector Laboratories) at 4°C for 30 min and given a final wash. 
Finally 4′,6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories) nucleus stain was added before mounting the 
cultures on glass microscope slides. Samples were then viewed 
by fluorescent microscopy.
Scanning electron microscopy
Cement constructs were prepared first, by mixing Cerament 
Spine Support powder to liquid ratio of 1 g/0.5 mL. BMP-7 
was added at a concentration of 0.4 mg/mL of cement.29 Nine 
constructs were prepared for rMSC seeding. After 1 or 3 
days of cell culture, rMSCs on the test material were pre-
pared according to a standard protocol for scanning electron 
microscopy (SEM) examination to allow the viewing of indi-
vidual cells.27 The cells were fixed with 1% glutaraldehyde 
(Sigma–Aldrich, USA) buffered in 0.1 M sodium cacodylate 
(Agar Scientific, Stanted, UK) at 4°C. The cells were then 
post-fixed in 1% osmium tetroxide (Agar Scientific, UK) 
and 1% tannic acid (Agar Scientific, UK) and then dehy-
drated through a series of alcohol concentrations (20%, 30%, 
40%, 50%, 60%, 70%, 90%, 96% and 100%). The final 
dehydration was in hexamethyl-disilazane (Sigma–Aldrich, 
UK), followed by air-drying. Once dry, the samples were 
sputter-coated with gold before examination with a Carl 
Zeiss Sigma VP Oxford Micro-analysis S800 or S4700 field 
emission SEM at an accelerating voltage of 10 kV.
rMSCs in collagen gel model
Collagen preparation. Collagen gels were used to mimic 
clinical tissue into which the material will eventually be 
injected. Collagen was prepared by using a rat-tail colla-
gen type-I that was treated with chloroform with a protein 
concentration of 2.05 mg/mL added to 0.6% acetic acid 
(Millipore Ltd, Temecula, CA, USA); 0.5 mL of 10× 
DMEM was added to 0.5 mL FCS, and then, 2.5 mL of the 
collagen was added simultaneously with 1 mL of 0.1 M 
NaOH. The addition of 0.1 M NaOH was needed to adjust 
the acidity of the collagen mixture to neutral until the colour 
turns to red; the universal tube was placed on an ice bath. 
Then, 1.5 mL of the mixture was poured in each well plate, 
using triplicates for each experiment. The mixture was then 
incubated at 37°C before cement/cell injection.
Injection of rMSCs and cement into collagen. For scaffold 
preparation, Cerament Spine Support was prepared by mix-
ing 3 g of the calcium sulphate/hydroxyapatite (CS/HA) 
(60:40) powder with 0.629 mL Cerament ⎪C-Tru (opacifier, 
BONESUPPORT, Lund, Sweden) solution and 103/0.6 mL 
cells suspension (in culture medium). Then, resultant 
formed paste was loaded into a 5-mL syringe. The liquid 
scaffold was injected into the prepared collagen using an 
18-gauge needle (Figure 1). The scaffold inside the collagen 
Table 1. Primer gene sequence for the assessed genes, their size and annealing temperatures.
Genes Primer sequence (5′–3′) (forward/reverse) Product size (bp) Annealing temperature (°C)
OPN Forward: G A C A G C C A G G A G A A G G A C A G 169 50
Reverse: T C T T C A C T C T T C G G C T C G A T
OCN Forward: G T G C A G A G T C T G G C A G A G G 153 50
Reverse: G G T T G A G C T C G C A C A C C T
GAPDH Forward: T G C C C T G G G G T G G G A A T G G A 200 45
Reverse: A G G G G T G A G G G A C A C G A G G C
OPN: osteopontin; OCN: osteocalcin; GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
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was incubated at 37°C and 5% CO2 overnight, and then, the 
collagen was detached from the sides of the well using a 
needle; then, fresh media was added to feed the cells. A 
live/dead stain was performed as described earlier.
Injection of cement into collagen followed by rMSCs 
seeding. Cerament Spine Support powder was mixed with 
Cerament ⎪C-Tru, with a powder-to-liquid ratio of 1 g/0.5 
mL, and immediately injected into the collagen. After 15 
min, 0.6 mL of rMSC suspension was injected between the 
CS/HA bone cement and incubated at 37°C and 5% CO2 
overnight. Then, live/dead staining was carried out using 
calcein-AM to stain viable cells and ethidium homodimer 
to stain compromised cells (Biolab, UK), following the 
same protocol described earlier.
Testing the osteogenic potential of CS/HA 
on rMSCs differentiation potential
The same collagen model was used as above: Cerament 
Spine Support powder was mixed with Cerament ⎪C-Tru, 
with a powder-to-liquid ratio of 1 g/0.5 mL, and immedi-
ately injected into the collagen; 0.6 mL of rMSC suspen-
sion was injected around the cement. The constructs were 
incubated for 21 days, at 95% humidity, 37°C and 5% CO2; 
the culture medium was changed twice a week. At day 21, 
immunofluorescent staining was carried out for rMSCs 
seeded on collagen using an OCN (AbD Serotec) primary 
antibody to assess the osteoinductive potential of the 
cement on the seeded cells following the same protocols as 
in the immunofluorescent cytoskeletal assessment.27 Cells 
were assessed and photographed using fluorescent micros-
copy, and random fields of view were chosen and imaged 
using Axiovision camera (Zeiss) as explained earlier. The 
osteogenesis was quantified by counting the percentage of 
cells labelled OCN with respect to a total cell count, which 
was performed by counting all the labelled nuclei which 
were stained by Hoechst stains (DNA stain).32
Results
Biocompatibility test
MTT. The percentage of viable MG-63 cells on the surface 
of the scaffold was similar for the two cements after the 
first 24 h. However, after 1 week of cell culture, the per-
centage of viable cells were 90.6% ± 12% and 77.0% ± 7% 
for Cerament Spine Support and Cerament Bone Void Filler 
cement, respectively. However, this difference in cell 
metabolism was not statistically significant (p > 0.05) when 
mean MTT values were compared (Figure 2).
Live and dead assay. The percentages of viable MG-63 
cells were 85.6% ± 11.7% and 82.0% ± 2% in the first 24 h 
for Cerament Spine Support cement and Cerament Bone 
Void Filler cement, respectively. At day 7 of cell culture, 
the mean value of viable cells were 145 ± 16.9 and 105 ± 
25.09 cells in well plate with Cerament Spine Support and 
Cerament Bone Void Filler, respectively; this difference 
was statistically significant (p < 0.05). Viable cells were 
Figure 1. The well plate which contains the prepared collagen 
constructs and the injectable cement: collagen construct (red) 
and the injected scaffold with cells (white).
Figure 2. Biocompatibility MTT toxicity assay using MG-63 cell 
line; the graph shows the percentage of proliferating cells based 
on mitochondrial enzyme activity of the cultured MG-63 live 
cells seeded on both cements, Cerament Bone Void Filler and 
Cerament Spinal Support, at different time points. On the x-axis 
is the different treatments done at 24 h, 72 h and at 1 week; the 
y-axis shows the percentage of proliferating cells calculated in 
different treatments. Purple and pink bars represent the Cerament 
Bone Void Filler cement and Cerament Spine Support cement, 
respectively. The figure indicates that at 1 week of cell culture, there 
was no statistically significant difference between the percentage 
of active proliferating live cells between Cerament Bone Void Filler 
and Cerament Spinal support (p > 0.05), after analysis using student 
t-test on SPSS software (error bar = SD, n = 3).
MTT: methyl thiazolyl tetrazolium; SD: standard deviation.
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found at a distance away from both cements, and typical 
images are shown in Figure 3.
Based on the biocompatibility testing, we decided to 
focus further studies on Cerament Spine Support cement as 
our preferred material due to the greater cell viability.
rMSCs harvesting, culturing and 
characterization
The methods used to isolate and expand the rMSCs 
required an average of 5 weeks for the cells to reach sub-
confluent status (approximately 1,000,000 cells/mL). 
Immunofluorescent staining for cell characterization 
showed positive staining for CD166 and CD44 and nega-
tive staining for CD34 surface markers, which indicated 
that the cells had mesenchymal stem cell characteristics. 
With regard to cell osteogenic potential, the immunofluo-
rescent stain for OCN, which is a late protein marker spe-
cific to osteoblastic expression, was positive on day 21 of 
treatment with osteogenic media (Figure 4(a)). 
Quantitatively, cells were seeded at day 0 at cell density of 
104 cells/cm2 at each cover slip and were cultured on osteo-
genic media; their count at day 21 was 381 × 104 cells/cm2.
mRNA expression profiles to test the osteogenic potential of 
rMSCs. Osteogenic differentiation potential was further 
Figure 3. Live and dead assays of (a) MG-63 cell proliferation and growth around Cerament Bone Void Filler and (b) MG-63 cell 
proliferation around Cerament Spine Support (scale bars = 70 µm).
Figure 4. (a) Cytoskeleton immunofluorescent images showing positive osteocalcin expression, actin (red) and DAPI (blue) stains at 
21 days of rMSCs culture (marker bars = 50 µm). (b) A scan image of gel RT-PCR of osteogenic lineage marker of rMSCs harvested 
after 21 days of cell culture showing a strong signal for osteocalcin (arrows) and weak signal for osteopontin gene expression.
DAPI: 4′,6-diamidino-2-phenylindole; RT-PCR: reverse transcriptase–polymerase chain reaction; rMSCs: rabbit mesenchymal stromal cells.
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confirmed by strong expression OCN using RT-PCR at 150 
bp and negative expression of OPN (Figure 4(b)). Prior to 
testing in collagen gel tissue mimics, we undertook short-
term biocompatibility (cytoskeletal and morphological) 
analysis of rMSCs on the Cerament Spine Support cement.
Immunofluorescent staining for cytoskeleton
rMSCs on the Cerament Spine Support attained a spread 
morphology on the surface of the material (Figure 5). 
rMSCs attained the required shape, size and adherence on 
the surface of the material.
SEM
A large number of rMSCs were adherent and were clearly 
visible on the surface of the Cerament Spine Support 
cement at all time points. At day 1, the rMSCs had started 
to adhere to the surface of the material and interact with the 
cement crystals (Figure 6). After day 3 of rMSC culture, 
there were areas where cells had proliferated well and 
aggregated with each other. Cells attained a typical size 
(60–160 µm in length), and they were polygonal or fusi-
form in shape (Figure 7). These cells had pseudopodia 
interacting with the crystals of the CS/HA cement (Figure 
8). Cells showed accompanying filamentous fibres forming 
on the surface; this may be evidence for extracellular 
matrix production (Figure 8). After ascertaining that the 
surfaces supported rMSC growth, we moved to the three-
dimensional (3D) model.
rMSCs in collagen model
Simultaneous injection of rMSCs and cement into colla-
gen. The live/dead assay of the constructs where the 
rMSCs and the cement were injected simultaneously into 
the collagen showed only dead cells in close apposition to 
the cement (Figure 9).
Injecting cement into collagen followed by rMSC seeding. In 
this collagen construct, many live cells were noted in the 
collagen gel with cell distribution when cell suspension 
was injected into the collagen between the cement, and live 
cells appeared green in colour (calcein-AM, Biolab), the 
percentage of live cells was 69.7% ± 12% after 24 h of cell 
seeding (Figure 10(a)). To provide a control for this, only 
experiment cells were injected into a collagen construct 
which showed even distribution of live cells inside collagen 
(Figure 10(b)). Understanding that sequential rather than 
parallel injection provided greater viability, we then inves-
tigated osteogenesis in vitro.
Testing osteogenic potential of CS/
HA cement on rMSCs osteospecific 
differentiation
Fluorescent microscopy showed positive expression for 
OCN, which indicates osteoblastic differentiation of the 
rMSCs injected around the Cerament Spine Support cement 
loaded within collagen. The percentage of the differentiated 
cells was 42.3% ± 17% (Figure 11(a)).
Discussion
The application of Cerament Spine Support or Cerament 
Bone Void Filler cement in combination with BMP-7 with 
rMSCs to stimulate muscle osteogenesis to reconstruct 
bone defects in the maxillofacial region is a novel concept, 
and hence was investigated in vitro. The potential potency 
of this technique is likely to stem from its ability to provide 
Figure 5. Cytoskeleton immunofluorescent image of rMSCs 
after 3 days of culture showing adherent and spread MSCs on 
the surface of Cerament Spine Support (marker bar = 50 µm).
rMSCs: rabbit mesenchymal stromal cells.
Figure 6. Scanning electron microscopy image showing rMSC 
(arrows) at day 1 of cell culture. The cell is covering micropore 
and is adherent onto the surface of the Cerament Spine Support 
cement (scale bar = 1 µm).
rMSCs: rabbit mesenchymal stromal cells.
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Figure 7. Scanning electron microscopy images of rMSCs attaining normal size (60–160 µm) and shape (polygonal and fusiform) on 
the surface of Cerament Spine Support after 3 days of culture (scale bars: (a), (b) and (d) = 10 µm and (c) 2 µm).
rMSCs: rabbit mesenchymal stromal cells.
Figure 8. Scanning electron microscopy images showing filopodia and lamellipodia of rabbit BMSCs (arrows) (a) extended over 
the filamentous fibres on surface of Cerament Spine Support and (b) attached and advancing over the crystal of Cerament Spine 
Support at 72 h (scale bars: (a) = 1 nm and (b) = 200 µm).
BMSCs: bone marrow stromal cells.
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simultaneously the three major requirements of tissue 
repair: space-filling scaffold, a source of progenitor cells 
and an inductive protein, BMP-7. Therefore, comprehen-
sive assessments of bio-scaffolds include the assessment of 
cell viability, and adhesion pattern on their surfaces are 
required.
Bone mineral–based composites remain an attractive 
choice for use as bone substitutes. Various mechanisms 
have been proposed for the role of CS in osteoconduction 
and/or osteoinduction in bone regeneration. While still not 
fully understood, it has been suggested that CS particles 
bind to adjacent bone and then resorb, providing a mecha-
nism to guide bone growth.33 Other studies indicate that CS 
increases the microvascular density in the CS-treated 
defects, suggesting a positive effect on angiogenesis. The 
resultant increase in vascularity may, in part, account for 
the biological effects of CS implants.34 A study by Walsh et 
al.35 showed that CS exerts a chemotactic effect. They also 
found increased concentrations of BMP-2 and BMP-7, 
transforming growth factor-β (TGF-β) and platelet-derived 
growth factor (PDGF), which play roles in connective tis-
sue regeneration. Alternatively, calcium ions are released 
during dissolution of CS, leading to local increases in 
calcium ion concentration, which may affect osteoblast 
genesis, function and differentiation. Therefore, the ele-
vated Ca2+ concentrations may inhibit osteoclast activity 
and tip the bone balance towards formation, similar to 
the mechanism following the resorptive phase of bone 
remodelling.36
There is evidence that calcium metaphosphate has been 
shown to stimulate the osteoblastic differentiation of human 
bone marrow stromal cells.37 It has also been shown by 
Lazary et al.38 that the proliferation and gene expression of 
mouse pre-osteoblastic cells on CS is also associated with 
increased alkaline phosphatase activity and gene expres-
sion associated with bone healing. The authors suggested 
that these effects might be due to the released calcium ions 
and might be mediated via SMAD3 (mothers against decap-
entaplegic homolog 3) receptors.39 An indirect mechanism 
of dissolution of CS was postulated to cause localized dem-
ineralization due to the increased acidity, thereby releasing 
growth factors previously incorporated into the bone 
matrix. Release of biomolecules, such as the BMPs, would 
enhance osteoblastic differentiation of MSCs and would 
consequently increase bone formation.35
Taken together, MTT and live/dead evaluation of bio-
compatibility after incubation of an osteoblast cell line, 
MG-63, on the cements showed significantly better results 
with regard to cell survival for Cerament Spine Support 
compared to the Cerament Bone Void Filler version of the 
CS/HA cement. This may be due to the toxic effect of the 
unreacted CS particles that causes local fluctuation in pH or 
ionic strength. Cerament Bone Void Filler has a lower liq-
uid-to-powder ratio, which may have left some unreacted 
CSH powder. A similar concept was reported with calcium 
phosphate cement (CPC) when a lower powder-to-liquid 
ratio was used.40,41 The literature supports the use of in vitro 
cell culture as a reliable and sensitive approach to evaluate 
the biocompatibility of the bio-scaffolds.12,24,39,42 In this 
study, MG-63s were chosen because of the high prolifera-
tion rate of this cell line, hence it was possible to evaluate 
the viability of the cells within the first week of cell 
culture.22
Assessment of rMSCs was carried out using a collagen 
model, which proved to be an effective model to guide to 
the best seeding technique to be used at the next preclinical 
stage of this study. These constructs provided a 3D in vitro 
mimic of the muscle to examine what might happen to the 
cells inside the scaffold when injected in vivo. The results 
showed that rMSCs could not be applied simultaneously 
with the injection of Cerament with retention of good via-
bility. The cells, however, could be successfully applied 
after 15 min from injection of the scaffold, allowing the 
material to start the setting process prior to the addition of 
the cells.
Qualitatively, rMSC viability assessments using direct 
cell seeding onto the materials and SEM and cytoskeleton 
evaluation showed that a large number of cells were adher-
ent and proliferating and also attained the typical morpho-
logical features of MSCs on the surface of the Cerament 
Spine Support. Similar SEM findings have been demon-
strated when rMSCs were seeded on surface of nano-HA/
polyamide 6 constructs.43 Furthermore, the cells went on to 
express OCN, typical of maturing osteoblasts.
This is the first multidisciplinary assessment to charac-
terize cell adhesion and function on these two types of CS/
HA cements, and it highlights the superiority of one com-
position over the other for our purposes. We appreciate and 
Figure 9. Live/dead assay (calcein-AM and ethidium 
homodimer) shows that compromised cells (red) are trapped 
inside cement on collagen construct after 24 h of cell culture 
(scale bar = 100 µm).
calcein-AM: acetomethoxy derivate of calcein.
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acknowledge that the materials are commercially available 
for clinical use and have passed the necessary biocompati-
bility tests. However, we are aspiring to achieve a novelty 
in the application of this material as a biomimetic injectable 
scaffold for future application in the reconstruction and 
replacement of the lost bone in the oro-facial region.
Conclusion
Our results show that Cerament Spine Support is the prefer-
able material for our purposes. The approach of testing the 
materials by injection into collagen constructs has shown 
the importance of timing in the application of both a CS-/
HA-injectable cement and rMSCs into soft tissue. In addi-
tion, this illustrates the need to use sequential injection first 
of cement and then cells in subsequent in vivo studies, 
which should lead to development of effective human 
protocols.
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which indicates the pre-osteoblast differentiation of the MSCs after seeding into the collagen around the CS/HA cement.
OCN: osteocalcin; CS/HA: calcium sulphate/hydroxyapatite; rMSCs: rabbit mesenchymal stromal cells.
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